
    
      A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess
      Quantitative Electroencephalography (qEEG) parameters after the administration of ketamine,
      two doses of AZD6765 and Placebo
    
  